Skip to main content
Publications
Pesantez D, Hoorn ST, Machado I, Garcia-Albeniz X, Rodriguez-Salas N, Heredia-Soto V, Vinal D, Pericay C, Garcia-Carbonero R, Losa F, Alonso V, Vera R, Batlle JF, Gallego J, Salud A, Nogue M, Layos L, Montagut C, Capdevila J, Vermeulen L, Maurel J, Fernandez-Martos C. Total neoadjuvant therapy with or without aflibercept in rectal cancer: three-year results of GEMCAD-1402. J Natl Cancer Inst. 2023 Dec 6;115(12):1497-505. doi: 10.1093/jnci/djad120
Schmiedl S, Fischer R, Ibanez L, Fortuny J, Thurmann P, Ballarin E, Ferrer P, Sabate M, Rottenkolber D, Gerlach R, Tauscher M, Reynolds R, Hasford J, Rottenkolber M. Tiotropium Respimat® vs. HandiHaler®: real-life usage and TIOSPIR trial generalizability. Br J Clin Pharmacol. 2016 Feb;81(2):379-88. doi: 10.1111/bcp.12808
Pavlovic M, Arnal-Estape A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albeniz X, Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis RR. Enhanced MAF oncogene expression and breast cancer bone metastasis. J Natl Cancer Inst. 2015 Sep 15;107(12):djv256. doi: 10.1093/jnci/djv256
Bui CL, Kaye JA, Castellsague J, Calingaert B, McQuay LJ, Riera-Guardia N, Saltus CW, Quinlan SC, Holick CN, Wahl PM, Suzart K, Rothman KJ, Wallander MA, Perez-Gutthann S. Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users. Curr Drug Saf. 2014 Mar;9(1):23-8.